Karl Martin Erik Åmark

This profile gathers the share dealings of Karl Martin Erik Åmark across 2 companies, led by Paolo Sarmientos and Xbrane Biopharma AB. Over a trading history stretching from 22 September 2017 to 17 January 2025, the count stands at 62 filings.

In open-market terms, that means 23 purchases worth €439k on one side and 30 sales worth €431k on the other. Taken together, the purchases exceed the sales by €8,538. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 2 share grants. So far in 2025, the count stands at 2 purchases and 2 sales.

Half of the purchases are above €13k and half below. Of 14 purchases, 11 formed part of a group of insiders buying within 30 days of each other. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

Most recently, on 20 January 2025, the filings show an open-market purchase worth €28k in Paolo Sarmientos. The median gap between a trade and its publication by Finansinspektionen is 3 days. Under the Market Abuse Regulation, managers have three business days to notify their trades. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Source: insider filings from Finansinspektionen. Past trades are no guide to future returns.